Track topics on Twitter Track topics that are important to you
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.
303-A College Road East
United States of America
Phone: (609) 613-4100
Fax: (609) 613-4150
Back in 2011 Gilead, and former CEO John Martin, stunned the market with the $11 billion acquisition of Pharmasset, a company developing a little-known drug known as PSI-7977. This went on to become ...
SummaryMarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an orga...
We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...
We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.
Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...